<DOC>
	<DOCNO>NCT01202071</DOCNO>
	<brief_summary>The purpose study compare pharmacodynamics/pharmacokinetics 5 mg , 10 mg , 20 mg 40 mg Rabeprazole sodium ( E3810 ) administer repeatedly daily 5 day healthy adult male Japanese participant . This single-center , open-label , randomize , four-treatment , four-way crossover study .</brief_summary>
	<brief_title>A Clinical Pharmacological Study Rabeprazole Sodium Japanese Healthy Adult Male Volunteers ( Study E3810 )</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>healthy adult Japanese male age 2040 body mass index 18.525 clinically significant abnormal physical examination , vital sign electrocardiogram use prescription medication , antacid , nutritional supplement , vitamin preparation , herbcontaining drug within previous 4 week use nonprescription medication within previous 1 week history drug alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Rabeprazole</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>healthy adult male Japanese subject</keyword>
</DOC>